The MRNA Vaccines and Therapeutics Market is Segmented by MRNA Construct Type (Conventional Non-Replicating MRNA, and More), Therapeutic Area (Infectious Diseases, Oncology, and More), Delivery System (Polymer-Based Nanocarriers, Cationic Nano-Emulsions, and More), Distribution Channel (Public and Private), and Geography (North America, Europe, and More). The Market and Forecasts are Provided in Terms of Value (USD).

The mRNA vaccine and therapeutics market size is estimated to be worth USD 9 billion in 2024 and is projected to be USD 1.99 billion by 2035, representing a CAGR of -23% during the forecast period from 2024 to 2035

Our Research report provides an overview of the mRNA therapeutics market includes global revenue (in $ million) for the base year data 2024, estimated data for 2025, and forecast data from 2026 to 2030.

• The global industry was valued at US$ 19.6 Bn in 2023
• It is anticipated to advance at a CAGR of 14.6% from 2024 to 2034 and reach US$ 85.9 Bn by the end of 2034

mRNA Vaccines and Therapeutics Market Scenario

Attribute	Detail
mRNA Vaccines and Therapeutics Market Drivers	Increase in Prevalence of Chronic Diseases Growth in R&D Activities and Industry-Academia Collaborations

Regional Outlook

Attribute	Detail
Leading Region	North America

mRNA Vaccines and Therapeutics Market Snapshot

Attribute	Detail
Market Size in 2023	US$ 19.6 Bn
Market Forecast (Value) in 2034	US$ 85.9 Bn
Growth Rate (CAGR)	14.6%
Forecast Period	2024-2034
Historical Data Available for	2020-2022
Quantitative Units	US$ Bn for Value
Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2023) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	mRNA Type Nucleoside-modified mRNA Unmodified mRNA Self-amplifying mRNA Type Prophylactic Therapeutic Application Infectious Diseases Oncology Rare Genetic Diseases Others (Respiratory Diseases, etc.) End-user Hospitals & Clinics Biopharmaceutical Companies Others (Research Organizations, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC
Companies Profiled	Moderna, Inc. BioNTech SE. CureVac SE Arcturus Therapeutics, Inc. Sanofi GSK plc Argos Therapeutics Inc. Ethris Pfizer Inc. AstraZeneca
Customization Scope	Available Upon Request
Pricing	Available Upon Request

The value of the global mRNA combined vaccines and therapies market is forecast to reach around ** billion U.S. dollars by the end of 2030. In 2020, the market was estimated at approximately ** billion U.S. dollars. This would represent a compound annual growth rate of nearly **** percent between 2020 and 2030.More information on the global mRNA vaccines and therapies market can be found here.

The mRNA therapeutics market is poised to witness substantial growth, with a market size of USD 12.17 billion in 2025 and projected to reach USD 61.14 billion by 2033, exhibiting a CAGR of 17.05% during the forecast period. The growth can be attributed to factors such as the increasing prevalence of infectious diseases, the rising incidence of chronic diseases, and the growing demand for personalized medicine. Additionally, the advancements in mRNA technology and the successful development of mRNA vaccines for COVID-19 have further accelerated the market growth. The mRNA therapeutics market is segmented based on application, type, end-use, and region. The infectious diseases segment is currently the largest application, owing to the high prevalence of infectious diseases worldwide and the potential of mRNA vaccines to provide effective protection. The prophylactic segment is expected to grow at a significant pace due to the increasing focus on preventive healthcare and the development of mRNA vaccines for a wider range of infectious diseases. The hospital and clinics segment is the major end-use segment, primarily due to the growing demand for mRNA-based therapies in treating various diseases in hospital settings. North America dominates the market, primarily due to the early adoption of mRNA technology, the presence of leading pharmaceutical companies, and the high prevalence of chronic diseases. The Asia Pacific region is expected to exhibit significant growth due to the increasing healthcare expenditure, the rising incidence of infectious diseases, and the growing awareness of mRNA-based therapies. The global mRNA therapeutics market is poised for exponential growth in the coming years. This cutting-edge technology holds immense promise for revolutionizing the treatment of various diseases. With an estimated market valuation of USD 20.5 billion in 2023, it is projected to reach a staggering USD 120 billion by 2030, exhibiting a remarkable CAGR of 24.1%. Recent developments include: In September 2023, Moderna, Inc. expanded its messenger ribonucleic acid research across oncology, respiratory, and rare diseases. This initiative was anticipated to fuel the company’s revenue , In August 2023, CureVac announced the commencement of dosing for the initial participant in a Phase 2 study. This study focuses on modified COVID-19 mRNA vaccine candidates developed through a collaboration with GSK Plc , In January 2023, BioNTech SE entered a strategic collaboration with the UK government to supply personalized messenger RNA cancer immunotherapies for up to 10,000 patients by 2030. This initiative positively impacted the company’s revenue , In January 2023, BioNTech SE completed the acquisition of InstaDeep Ltd. This initiative was anticipated to strengthen BioNTech’s AI-powdered drug discovery, design, and development .

The global mRNA vaccines and therapeutics market size reached USD 59.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 73.4 Billion by 2033, exhibiting a growth rate (CAGR) of 2.4% during 2025-2033. The development and acceptance of mRNA-based vaccines on a global scale, the growing need for quick and adaptable solutions for emerging and re-emerging infectious diseases, and the increasing incidence of cancer and genetic diseases are some of the major factors propelling the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Market Size in 2024	USD 59.2 Billion
Market Forecast in ​​​​​​​2033	USD 73.4 Billion
Market Growth Rate ​​​​​​​2025-2033	2.4%

IMARC Group provides an analysis of the key trends in each segment of the global mRNA vaccines and therapeutics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application, and end-user.

mRNA Therapeutics Market Outlook

According to our latest research, the global mRNA therapeutics market size reached USD 46.2 billion in 2024, demonstrating robust expansion on the back of increasing demand for advanced therapeutics and vaccines. The market is projected to grow at a CAGR of 13.7% from 2025 to 2033, reaching an estimated USD 150.6 billion by 2033. This impressive growth is primarily driven by continuous innovation in mRNA technology, rising investments in biotechnology, and the proven efficacy of mRNA-based products in combating infectious diseases and other chronic conditions, as per our latest research findings.

The growth trajectory of the mRNA therapeutics market is significantly influenced by the accelerated adoption of mRNA vaccines, especially following the global success of COVID-19 vaccines. Pharmaceutical and biotechnology companies are channeling substantial resources into mRNA research, recognizing its potential to revolutionize not only vaccines but also treatments for a range of diseases. The ability of mRNA technology to enable rapid development and scalable manufacturing of vaccines and therapeutics has positioned it as a preferred platform for addressing emerging infectious diseases, cancer, and genetic disorders. Furthermore, the versatility of mRNA therapeutics in targeting previously undruggable conditions is expanding its application scope, attracting both public and private sector investments. This influx of funding is fostering a robust pipeline of mRNA-based candidates, further propelling market expansion.

Another major growth factor is the increasing prevalence of chronic and infectious diseases worldwide, which has heightened the demand for innovative and effective treatments. mRNA therapeutics offer a unique mechanism of action that enables personalized and precision medicine approaches, particularly in oncology and rare genetic disorders. The adaptability of mRNA technology allows for the rapid customization of therapeutics to target patient-specific mutations, enhancing treatment outcomes and minimizing adverse effects. Regulatory bodies, recognizing the transformative potential of mRNA-based products, have streamlined approval processes for breakthrough therapies, further accelerating market entry and adoption. As a result, the mRNA therapeutics market is witnessing a surge in clinical trials and regulatory approvals, reinforcing its growth momentum.

Strategic collaborations and partnerships between academic institutions, research organizations, and pharmaceutical companies are also playing a pivotal role in advancing mRNA therapeutics. These alliances are fostering knowledge sharing, technological innovation, and efficient commercialization of novel mRNA products. The emergence of personalized mRNA therapeutics, which leverage patient-specific genetic information, is opening new frontiers in precision medicine, particularly for cancer and rare genetic diseases. Moreover, advancements in delivery technologies, such as lipid nanoparticles, are enhancing the stability and efficacy of mRNA therapeutics, overcoming previous limitations related to degradation and immune response. Collectively, these factors are not only driving market growth but are also shaping the future landscape of the global healthcare industry.

Regionally, North America dominates the mRNA therapeutics market, accounting for the largest share in 2024, driven by robust research infrastructure, significant investments, and the presence of leading market players. Europe follows closely, benefiting from supportive regulatory frameworks and active government funding. The Asia Pacific region is emerging as a lucrative market, fueled by rising healthcare expenditures, a growing patient pool, and increasing investments in biotechnology. Latin America and the Middle East & Africa are also witnessing gradual growth, supported by expanding healthcare infrastructure and rising awareness about advanced therapeutics. This regional diversity is fostering a dynamic and competitive global market environment.

Product Type An

mRNA Vaccines Market to grow at a significant CAGR 13.50% during 2021-2031. mRNA Vaccines Market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.

BCC Research Market Report says mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026, at compound annual growth rate of 16.8%

According to Cognitive Market Research, the global mRNA Therapeutics Market is driven by strong innovation and increasing adoption beyond COVID-19 vaccines into areas like oncology and rare disease Market Dynamics of mRNA Therapeutics Market

Key Drivers of mRNA Therapeutics Market

Government funding and policy support

Government funding and policy support have become pivotal drivers in accelerating the growth of the mRNA therapeutics market. National health bodies, global health alliances, and regulatory agencies are increasingly recognizing mRNA's potential for rapid-response vaccine development and personalized medicine.

For instance, Micron Biomedical recently announced that it won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and showcased its achievements at an event held during the J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco.

This has translated into substantial financial investments, fast-track approvals, and infrastructure-building initiatives aimed at boosting R&D and manufacturing capacity.

(Source:https://drug-dev.com/micron-biomedical-wins-2-million-barda-competition-for-its-collaboration-with-zipcode-bio-to-develop-mrna-based-broad-protecting-flu-vaccine-without-needles/)

Key Trends of mRNA Therapeutics Market

Expansion beyond infectious disease to oncology & rare diseases

The mRNA therapeutics market is undergoing a major transformation as its applications move beyond infectious diseases — the domain where it first gained global recognition during the COVID-19 pandemic — into oncology and rare genetic disorders. As mRNA technology matures beyond its initial success in infectious diseases, leading biopharmaceutical companies are rapidly advancing its use in oncology and rare genetic disorders.

For instance, BioNTech SE is set to present clinical trial results from selected pipeline candidates within its diverse oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled to take place in Chicago, IL, from May 30 to June 3, 2025. The data will showcase ongoing advancements in the Company’s clinical programs, which include a range of complementary therapeutic approaches such as mRNA cancer immunotherapies, next-generation immunomodulators, and targeted treatments like antibody-drug conjugates.

This reflects a broader industry shift toward harnessing mRNA and related technologies to target complex diseases with personalized, precision approaches, solidifying mRNA’s role as a foundational platform for future oncology innovation.

(Source:https://investors.biontech.de/news-releases/news-release-details/biontech-present-progress-across-diversified-oncology-pipeline) Introduction of mRNA Therapeutics Market

mRNA therapeutics represent a cutting-edge advancement in medical biotechnology, offering a novel approach to treating diseases by delivering synthetic messenger RNA into cells to produce therapeutic proteins. This technology gained global attention through the success of COVID-19 vaccines and is now being explored for a wide range of applications, including cancer immunotherapy, rare genetic disorders, and infectious diseases. Unlike traditional therapies, mRNA drugs are non-integrative, rapidly customizable, and capable of targeting diseases at the molecular level. Despite challenges related to delivery, stability, and immune response, ongoing innovations—such as improved lipid nanoparticles and self-amplifying mRNA are enhancing their clinical potential and positioning mRNA as a transformative platform in personalized medicine.

mRNA Vaccines and Therapeutics Market surges from USD 54.32 billion in 2024 to USD 253.83 billion by 2034 at 16.7% CAGR. Discover personalized medicine breakthroughs & lucrative cancer immunotherapy opportunities.

The global mrna vaccines and therapeutics market size is projected to grow from USD 53.14 billion in 2025 to USD 144.31 billion by 2033, exhibiting a CAGR of 13.3%.
Report Scope:

Report Metric	Details
Market Size in 2024	USD 46.91 Billion
Market Size in 2025	USD 53.14 Billion
Market Size in 2033	USD 144.31 Billion
CAGR	13.3% (2025-2033)
Base Year for Estimation	2024
Historical Data	2021-2023
Forecast Period	2025-2033
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Applications,By mRNA type,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,

Overview

New York, NY – Oct 29, 2025 – Global mRNA Therapeutics Market size is expected to be worth around US$ 40.3 Billion by 2033 from US$ 18.5 Billion in 2024, growing at a CAGR of 8.1% during the forecast period 2025 to 2033.

Messenger RNA (mRNA) therapeutics represent an innovative class of treatments designed to instruct human cells to produce specific proteins necessary for disease prevention or treatment. The approach utilizes synthetic mRNA sequences that mimic natural biological processes, enabling the body to generate therapeutic proteins directly rather than relying on external delivery. This technology has been widely recognized for its role in accelerating vaccine development, particularly during recent global health challenges.

The market for mRNA therapeutics is expanding due to strong research investments, advancements in delivery systems, and increasing clinical success rates across multiple therapeutic areas. The emergence of lipid nanoparticles (LNPs) and other delivery innovations has enhanced the stability and cellular uptake of mRNA formulations. These improvements have strengthened the commercial potential of mRNA-based medicines in infectious diseases, oncology, rare genetic disorders, and autoimmune conditions.

The growth of the mRNA therapeutics domain can be attributed to the rising demand for rapid-response platforms, personalized treatment options, and high-efficacy vaccines. Strategic collaborations between biopharmaceutical companies and research organizations continue to accelerate product pipelines and regulatory progress. In addition, expanding government funding and favorable reimbursement policies support continued innovation and adoption.

As clinical pipelines advance and more products transition toward approval, mRNA therapeutics are expected to transform modern medicine. The ability to rapidly design, manufacture, and adapt mRNA treatments positions this technology as a cornerstone of future healthcare solutions worldwide.

https://market.us/wp-content/uploads/2024/10/mRNA-Therapeutics-Market-Size.jpg" alt="mRNA Therapeutics Market Size" class="wp-image-131246">

REPORT ATTRIBUTE	DETAILS
MARKET SIZE ()
MARKET SIZE ()
CAGR (2023-2029)	%
HISTORIC YEAR
BASE YEAR
FORECAST YEAR
BY TYPE
BY APPLICATION
GEOGRAPHIC ANALYSIS	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
KEY PLAYERS	.

The value of the mRNA vaccine and therapeutics market in Latin America is forecast to reach around **** billion U.S. dollars by the end of 2023. In 2020, the market was estimated at approximately **** billion U.S. dollars and was expected to surpass **** billion U.S. dollars by 2030. From the total, the market for various types of cancer was the largest single market by disease group, worth over *** million U.S. dollars in 2023 .

More information on the mRNA vaccine and therapeutics market in various countries can be found here.

The Mrna Therapeutics report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

Find detailed analysis in Market Research Intellect's Mrna Vaccine And Therapeutics Market Report, estimated at USD 60 billion in 2024 and forecasted to climb to USD 120 billion by 2033, reflecting a CAGR of 8.5%.Stay informed about adoption trends, evolving technologies, and key market participants.

mRNA Vaccines & Therapeutics market has been steadily increasing over recent years, and forecasts suggest a substantial growth trajectory in the upcoming period.

ATTRIBUTES	DETAILS
STUDY PERIOD	2018-2031
BASE YEAR	2024
FORECAST PERIOD	2025-2031
HISTORICAL PERIOD	2018-2024
UNIT	VALUE (USD MILLION)
KEY COMPANIES PROFILED	Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology, Others
SEGMENTS COVERED	By Product Type - Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, Infection Prevention MRNA Vaccine By Application - Infectious Disease, Cancer, Other By Sales Channels - Direct Channel, Distribution Channel By Geography - North America, Europe, Asia-Pacific, South America, Middle East and Africa

The global mRNA vaccines and therapeutics market size was over USD 22.21 billion in 2025 and is anticipated to witness a CAGR of more than 15.2% from 2026 to 2035, due to the wide application of messenger technology.